Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide in Participants With Impaired Liver Function

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~All Participants:~* Women of childbearing potential are excluded from the study.~* Women not of childbearing potential may participate and include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis; or postmenopausal~* Are between the body mass index (BMI) of 19.0 and 40.0 kilograms per meter squared (kg/m²), inclusive, at screening~Healthy Participants:~- Healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal liver function~Participants with Impaired Liver Function:~* Males or females with chronic mild, moderate and severe liver impairment, assessed by Child-Pugh scoring~* Have type 2 diabetes mellitus (T2DM) controlled with diet or exercise alone or on stable doses of metformin for at least 8 weeks~* Have a hemoglobin A1c (HbA1c) ≥6.0% and ≤11.0% at screening~Exclusion Criteria:~All Participants:~* Have known allergies to tirzepatide or related compounds~* Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2~* Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase or GI disorder (eg, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors~Participants with Impaired Liver Function:~* Have hemoglobin \<8.5 grams per deciliter (g/dL)~* Have kidney function that is significantly impaired at screening~* Have taken any glucose-lowering medications other than metformin, including insulin, in the past 3 months before screening~* Have brain function impaired significantly due to liver condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Normal Hepatic Function (Type: ACTIVE_COMPARATOR): Participants with normal hepatic function received single subcutaneous dose of 5 milligrams (mg) tirzepatide.
- Mild Hepatic Impairment (Type: EXPERIMENTAL): Participants with mild hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.
- Moderate Hepatic Impairment (Type: EXPERIMENTAL): Participants with moderate hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.
- Severe Hepatic Impairment (Type: EXPERIMENTAL): Participants with severe hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.

Based on this trial design, predict the completion outcome and termination type (if applicable).